Skip to main navigation Skip to search Skip to main content

Validation of Neutral Ceramidase (NCD) as a Novel Target for Therapy of Colon Cancer Validation for neutral ceramidase (NCD) as a novel target for therapy of ischemia and reperfusion-induced acute kidney injury

Project: Research

Project Details

StatusFinished
Effective start/end date02/1/15 → 10/31/18

Funding

  • Ono Pharmaceutical Company Limited: $907,180.25